Roche cites COVID-19 and biosimilars in Q2 decline

Much of that decline can be attributed to increasing biosimilar competition to three of Roche’s key cancer therapies – Herceptin (trastuzumab), Avastin (bevacizumab) and Rituxan (rituximab).

EMA fast-tracks review of AZ/Daiichi Sankyo’s HER2 drug

The drug presents a new challenge to Roche’s dominant position in the HER2-positive breast cancer market, which includes a trio of targeted treatments – Herceptin (trastuzumab), Perjeta (pertuzumab) and Kadcyla ... The FDA approval and EMA

Cortellis Drugs to Watch in 2020 report

It has entered into a market dominated by Herceptin and other HER2-targeted therapies such as Perjeta and Tykerb.

Roche’s Herceptin/Perjeta fixed-dose combo filed with FDA

Last year, sales of Herceptin were flat overall at around $7bn, but fell 16% in Europe and Japan as biosimilars started to gather momentum. ... Perjeta has been growing strongly – rising a third to $2.8bn last year – thanks to data showing it

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]